In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IN VIVO’s Deals Of The Month: October 2015

Executive Summary

IN VIVO’s editors pick October's top alliance, financing and M&A deals (free with registration).

You may also be interested in...



Endologix/TriVascular Tout Breadth Of AAA Indications Offered By Combined Firm

Endologix will acquire TriVascular Technologies in a $211 million deal expected to close in January. Company execs say they will now be better prepared to go up against larger players in the abdominal aortic aneurysm endovascular device space, offering the broadest set of AAA indications on the market.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

In Vivo's Deals Of The Month, January 2018

In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel